Vicor Technologies Establishes Captive Lease Program for Purchase of its PD2i Analyzer™
News Jan 24, 2011
David H. Fater, CEO of Vicor Technologies, Inc. has announced that Vicor has established a captive lease program with Coastal Leasing, Inc. to provide a financing option for purchase of its PD2i Analyzer™. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software.
Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.
"Our newly-established captive lease program with Coastal Leasing represents a true win/win. Purchasers of our PD2i Analyzer™ now have access to a financing option through an established, reputable provider of equipment lease financing options that enables them to securely payout their purchase should they wish to do so, and Vicor has immediate access to the revenue generated on financed purchases to further our growth initiatives," stated Mr. Fater.
Coastal Leasing, Inc., established in 1980, is a progressive, service-oriented provider of equipment lease financing to a wide spectrum of industries on a national basis. Based in Ft. Lauderdale, FL, Coastal Leasing funds transactions via a full range of financial products, including tax-oriented (true) leases, lease purchases (lease finance agreements), master lease lines, sale/leasebacks, and chattel mortgages/loan and security agreements.
Researchers have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE